ORONTO and HAIFA, Israel, Nov. 01, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company developing exosome-based therapies for the multi-billion dollar regenerative medicinei market, is pleased to announce, further to its press release dated September 26, 2024 (the “September

TORONTO and HAIFA, Israel, Oct. 23, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company developing exosome-based therapies for the multi-billion dollar regenerative medicinei market, announced its invitation to present at two conferences in exosome science this November in the

TORONTO and HAIFA, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company developing exosome-based therapies for the multi-billion dollar regenerative medicinei market, is pleased to announce a non-brokered private placement of up to 3,636,363 units (“Units”) at

TORONTO and HAIFA, Israel, Sept. 12, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company developing exosome-based therapies for the multi-billion dollar regenerative medicinei market, is pleased to announce its participation in a series of prestigious conferences this October. These events

TORONTO and HAIFA, Israel, Sept. 06, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”) is pleased to announce compelling new findings that highlight the therapeutic potential of ExoPTEN for patients with spinal cord injuries. In a recent preclinical study using a

TORONTO and HAIFA, Israel, Aug. 23, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”) is pleased to announce that its Chief Executive Officer, Dr. Lior Shaltiel, has been invited to speak at the upcoming Bioprocess International Conference being held from September 23 –

TORONTO and HAIFA, Israel, Aug. 15, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”) is pleased to announce significant advancements in their manufacturing process of exosomes. Exosomes, which are naturally released by cells, hold immense promise for regenerative medicine and they

TORONTO and HAIFA, Israel, Aug. 09, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the “Company” or “NurExone”) is pleased to announce new data for its ExoPTEN nanodrug, marking a significant step towards commercial-grade manufacturing. Building on the announcement of a new Good Manufacturing Practice

TORONTO and HAIFA, Israel, July 29, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company developing regenerative medicine therapies, is pleased to announce that the Israel Patent Office recently issued a Notice of Allowance for an ExoPTEN patent,

A pioneering biopharmaceutical company, is pleased to announce the preliminary results from a small-scale controlled study exploring the use of its flagship nanodrug, ExoPTEN, for optic nerve recovery in a rat model at Sheba Medical Center. This study marks a second clinical indication being investigated for ExoPTEN. The study was